Danielle A Bischof1, Yuhree Kim1, Dan G Blazer2, Ramy Behman3, Paul J Karanicolas3, Calvin H Law3, Fayez A Quereshy4, Shishir K Maithel5, T Clark Gamblin6, Todd W Bauer7, Timothy M Pawlik8. 1. Department of Surgery, The Johns Hopkins University, Baltimore, MD. 2. Department of Surgery, Duke University, Durham, NC. 3. Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Department of Surgery, University of Toronto, Toronto, ON, Canada. 4. Department of Surgery, University of Toronto, Toronto, ON, Canada; University Health Network, Toronto, ON, Canada. 5. Department of Surgery, Emory University, Atlanta, GA. 6. Medical College of Wisconsin, Milwaukee, WI. 7. Department of Surgery, University of Virginia, Charlottesville, VA. 8. Department of Surgery, The Johns Hopkins University, Baltimore, MD. Electronic address: tpawlik1@jhmi.edu.
Abstract
BACKGROUND: Patients with advanced gastrointestinal stromal tumors (GIST) are at high risk for recurrence after surgery. The aim of this study was to characterize outcomes of advanced GIST treated with surgery from a large multi-institutional database in the tyrosine kinase inhibitor (TKI) era. STUDY DESIGN: Patients who underwent surgery for an advanced GIST from 1998 through 2012 were identified. Demographic, clinicopathologic, perioperative, and survival data were collected and analyzed. RESULTS: There were 87 patients with locally advanced GIST and 71 patients with recurrent/metastatic GIST. The vast majority (95%) of patients with locally advanced GIST required a multivisceral resection; most patients (87%) underwent a microscopically complete (R0) resection. Although 82% of patients had high-risk tumors according to modified NIH criteria or had recurrent/metastatic disease, only 56% of patients received adjuvant TKI therapy. Among patients with locally advanced GIST, 3-year recurrence-free survival and overall survival rates were 65% and 87%, respectively. In contrast, 3-year recurrence-free survival and overall survival rates among patients with recurrent/metastatic GIST were 49% and 82%, respectively. On multivariate analysis, predictors of worse outcomes included high mitotic rate and male sex for patients with locally advanced GIST, and age and lack of adjuvant TKI therapy were associated with adverse outcomes among patients with recurrent/metastatic GIST (all p < 0.05). CONCLUSIONS: Resection of advanced GIST can be safely accomplished with high rates of R0 resection. Among patients with advanced GIST, TKI therapy was underused. Barriers to the use of TKI therapy in this population should be explored.
BACKGROUND:Patients with advanced gastrointestinal stromal tumors (GIST) are at high risk for recurrence after surgery. The aim of this study was to characterize outcomes of advanced GIST treated with surgery from a large multi-institutional database in the tyrosine kinase inhibitor (TKI) era. STUDY DESIGN:Patients who underwent surgery for an advanced GIST from 1998 through 2012 were identified. Demographic, clinicopathologic, perioperative, and survival data were collected and analyzed. RESULTS: There were 87 patients with locally advanced GIST and 71 patients with recurrent/metastatic GIST. The vast majority (95%) of patients with locally advanced GIST required a multivisceral resection; most patients (87%) underwent a microscopically complete (R0) resection. Although 82% of patients had high-risk tumors according to modified NIH criteria or had recurrent/metastatic disease, only 56% of patients received adjuvant TKI therapy. Among patients with locally advanced GIST, 3-year recurrence-free survival and overall survival rates were 65% and 87%, respectively. In contrast, 3-year recurrence-free survival and overall survival rates among patients with recurrent/metastatic GIST were 49% and 82%, respectively. On multivariate analysis, predictors of worse outcomes included high mitotic rate and male sex for patients with locally advanced GIST, and age and lack of adjuvant TKI therapy were associated with adverse outcomes among patients with recurrent/metastatic GIST (all p < 0.05). CONCLUSIONS: Resection of advanced GIST can be safely accomplished with high rates of R0 resection. Among patients with advanced GIST, TKI therapy was underused. Barriers to the use of TKI therapy in this population should be explored.
Authors: Mark Fairweather; Vinod P Balachandran; George Z Li; Monica M Bertagnolli; Cristina Antonescu; William Tap; Samuel Singer; Ronald P DeMatteo; Chandrajit P Raut Journal: Ann Surg Date: 2018-08 Impact factor: 12.969
Authors: Christina L Roland; Brian K Bednarski; Kelsey Watson; Keila E Torres; Janice N Cormier; Wei-Lien Wang; Alexander J Lazar; Neeta Somaiah; Kelly K Hunt; Barry W Feig Journal: J Surg Oncol Date: 2018-02-15 Impact factor: 3.454
Authors: Michael J Cavnar; Kenneth Seier; Mithat Gönen; Christina Curtin; Vinod P Balachandran; William D Tap; Cristina R Antonescu; Sam Singer; Ronald P DeMatteo Journal: J Gastrointest Surg Date: 2020-11-09 Impact factor: 3.267
Authors: Rebecca M Platoff; William F Morano; Luiz Marconcini; Nicholas DeLeo; Beth L Mapow; Michael Styler; Wilbur B Bowne Journal: Case Rep Oncol Med Date: 2017-11-30